Christopher McCabe and colleagues examine the claims behind the decision not to reduce drug costs in the multiple sclerosis risk sharing scheme
No takes yet. Share an insight, caveat, or question.
McCabe et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: